Erwinia asparaginase with chemo for new ALL or LBL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 54 years old, with a body mass index (BMI) of 30 or higher if under 40, or any BMI if 40 to 54.
- You have been diagnosed with a type of leukemia called Philadelphia chromosome-negative ALL or lymphoblastic lymphoma (LBL).
- Your liver, kidney, and heart function are within acceptable limits based on recent blood tests.
- You have not received previous treatment with any asparaginase drug.
- You agree to use effective birth control during treatment and for at least 6 months after (12 months if receiving rituximab).
- You do not have active infections, certain heart conditions, or a history of severe pancreatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (EPOCH) plus a targeted therapy (ponatinib) for patients with a specific type of acute lymphoblastic leukemia (Ph+ ALL). Some participants also get rituximab if their leukemia cells have a certain marker (CD20). The goal is to see how well this treatment works as a first therapy.
This trial tests a new combination of three drugs for patients with relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia. It aims to see if adding the drugs venetoclax and asparaginase to blinatumomab can improve outcomes.
This trial tests a treatment plan for people with a certain type of acute lymphoblastic leukemia (ALL) called B-lineage ALL. It aims to see how well the treatment works and how safe it is.
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
This trial tests a new combination of drugs for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see if this combination is safe and effective in treating the disease.
This trial tests a treatment plan for adults with a type of blood cancer called ALL that is newly diagnosed and not Philadelphia chromosome-positive. The goal is to see how well the treatment works and if it is safe for patients who have not had prior therapy.
Hear when a new Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.